WallStSmart

Insmed Inc (INSM)vsMaravai Lifesciences Holdings Inc (MRVI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 226% more annual revenue ($606.42M vs $185.74M). INSM leads profitability with a -2.1% profit margin vs -70.4%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

MRVI

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: 0.95

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

MRVI2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

MRVI4 concerns · Avg: 2.5/10
Market CapQuality
$1.13B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-48.6%2/10

ROE of -48.6% — below average capital efficiency

Revenue GrowthGrowth
-11.8%2/10

Revenue declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : MRVI

The strongest argument for MRVI centers on Debt/Equity, Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : MRVI

The primary concerns for MRVI are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

MRVI generates stronger free cash flow (-25M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Maravai Lifesciences Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?